Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2′-deoxycytidine

Carcinogenesis

Volumn 35, Issue 1, 2014, Pages 138-144

  Chik, Flora ^a   Machnes, Ziv ^a   Szyf, Moshe ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; GELATINASE A; S ADENOSYLMETHIONINE; UROKINASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RISK; CELL CYCLE PROGRESSION; CELL INVASION; CELL STRAIN MCF 7; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MATRIX METALLOPROTEINASE 2; MCF-7 CELLS; S-ADENOSYLMETHIONINE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84891349423     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt284     Document Type: Article

References (38)

1. Baylin,S.B. et al. (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer, 11, 726-734.
2. Szyf,M. (1994) DNA methylation properties: consequences for pharmacology. Trends Pharmacol. Sci., 15, 233-238.
3. Szyf,M. (2001) The role of DNA methyltransferase 1 in growth control. Front. Biosci., 6, D599-D609.
4. Fenaux,P. (2005) Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat. Clin. Pract. Oncol., 2 (suppl. 1), S36-S44.
5. Feinberg,A.P. et al. (1988) Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res., 48, 1159-1161.
6. Dante,R. et al. (1992) Methylation patterns of long interspersed repeated DNA and alphoid repetitive DNA from human cell lines and tumors. Anticancer Res., 12, 559-563.
7. Rosty,C. et al. (2002) Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol., 160, 45-50.
8. Pakneshan,P. et al. (2003) Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J., 17, 1081-1088.
9. Shteper,P.J. et al. (2003) Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene, 22, 7737-7749.
10. Stefanska,B. et al. (2011) Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res., 71, 5891-5903.
11. Chik,F. et al. (2011) Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis, 32, 224-232.
12. Ateeq,B. et al. (2008) Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia, 10, 266-278.
13. Guo,Y. et al. (2002) Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J. Biol. Chem., 277, 41571-41579.
14. Yu,Y. et al. (2010) Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One, 5, e12710.
15. Pakneshan,P. et al. (2004) Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem., 279, 31735-31744.
16. Shukeir,N. et al. (2006) Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res., 66, 9202-9210.
17. Detich,N. et al. (2003) The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J. Biol. Chem., 278, 20812-20820.
18. Karimi,M. et al. (2006) LUMA (LUminometric Methylation Assay)-a high throughput method to the analysis of genomic DNA methylation. Exp. Cell Res., 312, 1989-1995.
19. Karimi,M. et al. (2006) Using LUMA: a luminometric-based assay for global DNA-methylation. Epigenetics, 1, 45-48.
20. Rio,D.C. et al. (2010) Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb. Protoc., 2010, pdb.prot5439.
21. Clark,S.J. et al. (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res., 22, 2990-2997.
22. Chen,R.Z. et al. (1998) DNA hypomethylation leads to elevated mutation rates. Nature, 395, 89-93.
23. Lengauer,C. et al. (1997) DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl Acad. Sci. USA, 94, 2545-2550.
24. Duffy,M.J. (2002) Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. Biochem. Soc. Trans., 30, 207-210.
25. Pakneshan,P. et al. (2005) Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr. Cancer Drug Targets, 5, 471-488.
26. Li,H.C. et al. (2004) Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res. Treat., 88, 75-85.
27. Xiao,L. et al. (2010) Identification of a novel human cancer/testis gene MAEL that is regulated by DNA methylation. Mol. Biol. Rep., 37, 2355-2360.
28. Roll,J.D. et al. (2008) DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer, 7, 15.
29. Hasan,M.K. et al. (2008) CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53- HDM2-p21WAF1 pathway. Int. J. Oncol., 32, 663-671.
30. Pulukuri,S.M. et al. (2005) Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int. J. Oncol., 26, 863-871.
31. Ying,J. et al. (2004) Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood, 103, 743-746.
32. Schmelz,K. et al. (2005) 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int. J. Cancer, 114, 683-695.
33. Merlo,A. et al. (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1, 686-692.
34. Itzykson,R. et al. (2012) Optimizing hypomethylating agents in myelodysplastic syndromes. Curr. Opin. Hematol., 19, 65-70.
35. Anderson,O.S. et al. (2012) Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J. Nutr. Biochem., 23, 853-859.
36. Scott,S.A. et al. (2006) 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leuk. Res., 30, 69-76.
37. Gagnon,J. et al. (2003) Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer. Drugs, 14, 193-202.
38. Yuan,Y. et al. (2005) Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int. J. Cancer, 113, 654-659.